Proactive Population Health Management of Cardiovascular Disease in Primary Care Using the PROSPERA-program.

Summary

The PROSPERA-program is a complex multilevel approach that includes training for healthcare providers, a risk assessment process, and decision support tools to help match patients with the appropriate treatment based on their care needs.

The goal of this clinical trial is to determine if the PROSPERA-program can improve the cardiovascular risk profile in patients aged 40-90 years enrolled in primary care programs for increased cardiovascular risk, such as cardiovascular disease, increased vascular risk, or diabetes.

The main question it aims to answer is:

• Does the cardiovascular risk profile improve for patients using the PROSPERA-program?

Researchers will compare the PROSPERA-program with standard cardiovascular care to see if the program enhances cardiovascular population health in primary care.

Additionally, the study will assess how well the PROSPERA-program fits into the workflow of primary care providers and supports shared decision-making.

Participants will:

* Receive a consultation with their general practitioner or practice nurse according to the PROSPERA-program.
* Have their routinely collected healthcare data used for evaluation.
* Be asked to complete a questionnaire or participate in an interview (for a subset of patients).

Conditions

• Cardiovascular Diseases

Interventions

OTHER

PROSPERA-program

The PROSPERA-program consists of the following components: 1. Health care provider training and education about U-Prevent and cardiovascular risk communication. 2. Risk stratification: proactive selection of cardiovascular patients through the PROSPERA-empanelment procedure - for the population with increased cardiovascular risk, prior to consultation. 3. Decision support tools: use of the Lifestylecheck and the U-Prevent clinical decision support tool to guide motivated shared decision making towards appropriate care matched to the care complexity of the patient - for the individual patient, during consultation.

Sponsors & Collaborators

• UMC Utrecht

  collaborator OTHER

• Leiden University Medical Center

  lead OTHER

Principal Investigators

• Rimke C Vos · LUMC

• Mattijs E Numans · LUMC

• Jannick AN Dorresteijn · UMC Utrecht

• Hendrikus JA van Os · LUMC

Study Design

Allocation

RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

40 Years

Max Age

90 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2025-02-17

Primary Completion

2026-07-09

Completion

2026-07-09

Countries

• Netherlands

Study Locations